Core Insights - Thiogenesis Therapeutics has received scientific advice from the European Medicines Agency (EMA) supporting its submission for an Investigational Medicinal Product Dossier (IMPD) for a Phase 2a clinical trial in pediatric patients with metabolic dysfunction-associated steatohepatitis (MASH) [1][2] - The trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of TTI-0102 in children aged 10 to 17 with biopsy-confirmed MASH [2] - Thiogenesis has also been granted a European Union patent for its asymmetric disulfide prodrugs of cysteamine, which secures its competitive position in mitochondrial and metabolic disease indications until 2038 [3] Company Overview - Thiogenesis Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, focusing on developing thiol-based therapies for mitochondrial diseases and pediatric metabolic conditions [8] - The company is publicly traded on the TSX Venture Exchange and OTCQX, with its lead product candidate, TTI-0102, currently in clinical trials for various serious pediatric conditions [8] Product Details - TTI-0102 is a third-generation disulfide prodrug of cysteamine, designed to address challenges associated with earlier thiol-based drugs, including short half-life and adverse side effects [5][6] - The prodrug aims to enhance the bioavailability of cysteamine, which is crucial for producing antioxidants and restoring mitochondrial function [6][7] Industry Context - Pediatric MASH is a severe form of fatty liver disease affecting approximately 7-14% of children and adolescents in the EU, translating to 5-10 million patients [4] - The condition is characterized by liver inflammation and damage due to fat accumulation, with oxidative stress playing a significant role in its progression [4]

Company Overview - Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company focused on developing sulfur-based therapeutics for rare pediatric and inherited mitochondrial disorders [2][10] - The company is publicly traded on the TSX Venture Exchange and OTCQX [10] Clinical Programs - The company is advancing two lead Phase 2 clinical programs for its novel thiol drug, TTI-0102 [3] - A European multicenter trial for Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS), initiated on May 14, 2025 [3] - A U.S.-based trial for the Leigh Syndrome Spectrum (LSS), following FDA clearance of the Investigational New Drug (IND) application on June 11, 2025 [3] Drug Candidate - TTI-0102 is a next-generation thiol-based prodrug designed to enhance intracellular levels of glutathione and taurine, which are critical for mitigating oxidative stress in mitochondrial disorders [3][8] - The drug is engineered to address challenges faced by first-generation thiol-based drugs, including short half-life and adverse side effects [8] Mitochondrial Disorders - MELAS is characterized by symptoms such as seizures, muscle weakness, and can lead to loss of motor skills and intellectual disability, affecting approximately 4.1 in 100,000 of the population [7] - LSS is diagnosed in about 1 in 40,000 births and presents symptoms like impaired feeding, loss of motor skills, and seizures, with no current cure available [6] Conference Participation - The company’s CEO, Dr. Patrice Rioux, will participate in a clinical panel discussion at the United Mitochondrial Disease Foundation's 2025 Mitochondrial Medicine Conference, which gathers over 700 scientists and industry stakeholders [2][3]

Core Points - Thiogenesis Therapeutics has activated a second clinical site in France for its Phase 2 clinical trial of TTI-0102, targeting MELAS patients [1][2] - The trial is enrolling 12 patients, with 8 receiving TTI-0102 and 4 receiving a placebo, and is set to conduct a three-month interim analysis in September 2025 [3][4] - Key clinical endpoints include the 12-Minute Walk Test, Fatigue Severity Scale, and WHOQOL-BREF Quality of Life assessment [4] Company Overview - Thiogenesis Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, focusing on sulfur-based therapeutics for pediatric and inherited mitochondrial diseases [9] - The lead product candidate, TTI-0102, is designed to improve upon first-generation thiol-based drugs by addressing issues like short half-life and side effects [6][7] - The company is publicly traded on the TSX Venture Exchange and OTCQX, and is also planning trials for other conditions such as Leigh syndrome and Rett syndrome [9] Disease Background - MELAS is an inherited mitochondrial disorder, often caused by a mutation in the MT-TL1 gene, with symptoms including seizures, muscle weakness, and fatigue [5] - It is estimated that approximately 4.1 out of 100,000 people worldwide are affected by MELAS [5] - The disease typically presents before the age of 20 and is considered an orphan disease despite its prevalence [5] Product Information - TTI-0102 is an asymmetric disulfide prodrug that acts as a precursor to cysteamine, a thiol compound involved in key biochemical reactions [6][7] - Prodrugs like TTI-0102 can enhance the bioavailability of active ingredients and reduce side effects, facilitating regulatory approval processes [8]

Company Overview - Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company based in San Diego, California, publicly traded on the TSX Venture Exchange and OTCQX [2] - The company is focused on developing sulfur-containing prodrugs aimed at treating serious pediatric diseases with unmet medical needs [2] Product Development - Thiogenesis' lead product candidate, TTI-0102, is currently in an active Phase 2 clinical trial for Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS) [2] - The company is planning to initiate clinical trials for additional conditions including Leigh syndrome, Rett syndrome, and pediatric MASH [2] Recent Corporate Actions - On June 11, 2025, the company's board of directors approved a grant of 400,000 common share purchase options at an exercise price of $0.77 to two directors [1] - The options will vest at a rate of 25% every six months and will expire on June 11, 2030 [1]

Core Insights - TETRA Technologies, Inc. will host an Investor Day on September 25, 2025, at the New York Stock Exchange to outline its strategic objectives and growth initiatives for the next five years [1][3] - The company has received the 2025 Hart Energy Special Meritorious Engineering Award for its TETRA Oasis Total Desalination Solution, recognizing its innovative contributions to sustainable water management [4] Company Overview - TETRA Technologies, Inc. operates globally across six continents, focusing on environmentally conscious services and solutions in energy services, industrial chemicals, and critical minerals [5] - The company is expanding into the low-carbon energy market, leveraging its chemistry expertise and mineral resources to meet the demand for sustainable energy [5] Investor Day Details - The Investor Day will provide insights into TETRA's operational achievements and technical strengths in fluid chemistry solutions, particularly for energy and industrial chemicals [2] - The event will include a Q&A session and showcase videos of TETRA's latest innovations and R&D efforts from its Technology Center in Conroe, Texas [2]

Summary of TETRA Technologies (TTI) Conference Call Company Overview - TETRA Technologies has been operating for over 40 years, providing diverse revenue streams from energy services and industrial chemicals across the United States and 23 other countries [3][4] - The company is recognized as an industry innovation leader, particularly in completion fluids, oil and gas water treatment, and water management services [4] Financial Performance - TETRA reported a strong first quarter with adjusted EBITDA margins of 36% for completion fluids and 13% for water and flowback services [5] - The industrial chemicals segment achieved its highest first-quarter revenue and adjusted EBITDA in history [5] - Trailing twelve months revenue reached $327 million, reflecting a nearly 50% growth since the second year of COVID in 2021 [7] - The company has a solid balance sheet with a leverage ratio of 1.5 times and no debt maturities until 2029 and 2030 [29] Market Position and Growth Strategies - TETRA is positioned in key markets, including deepwater and unconventional markets in North America, Latin America, and the Middle East [4] - The company is focusing on three emerging growth strategies: 1. **Electrolytes for Energy Storage**: TETRA has developed a zinc bromide-based electrolyte for long-duration energy storage, partnering with Eos Technologies [13][14] 2. **Produced Water Desalination**: The company is introducing a desalination solution for produced water, targeting markets such as agriculture and industry [18][20] 3. **Critical Minerals Production**: TETRA has secured over 40,000 acres of brine leases in Arkansas, rich in lithium, bromine, magnesium, and manganese [22][24] Industry Trends and Challenges - The deepwater market is projected to grow at a 7% CAGR through 2028, with TETRA maintaining a strong market share [9] - The company is addressing challenges in the Permian Basin, where produced water disposal capacity is becoming limited, necessitating innovative solutions [19][20] - TETRA's technology investments are expected to enhance margins and operational efficiency, particularly in the water and flowback segment [11][12] Key Collaborations and Innovations - TETRA has collaborated with EOG Resources for produced water beneficial reuse and desalination pilot projects, achieving a 92% desalination rate in initial tests [21][20] - The company is leveraging automation technologies to reduce manpower requirements in operations, enhancing efficiency [12] Conclusion - TETRA Technologies is well-positioned for growth with a solid financial foundation, innovative technologies, and strategic partnerships, despite facing industry challenges [30]

Company Overview - TETRA Technologies, Inc. is an energy services and solutions company focused on environmentally conscious services and solutions [3] - The company operates on six continents and has a portfolio that includes Energy Services, Industrial Chemicals, and Critical Minerals [3] - TETRA provides products and services to the oil and gas industry and calcium chloride for various applications, while also expanding into the low-carbon energy market [3] Investor Conferences - TETRA's senior management will participate in two investor conferences in early June, including the Stifel 2025 Boston Cross Sector 1x1 Conference on June 4 [2] - CEO Brady Murphy and CFO Elijio Serrano will host one-on-one meetings with institutional investors at the Stifel conference [2] - VP of Investor Relations Kurt Hallead will also host one-on-one meetings at the RBC 2025 Capital Markets Global Energy, Power & Infrastructure Conference on June 4 [2]

Company Overview - TETRA Technologies, Inc. is an energy services and solutions company focused on environmentally conscious services and solutions that enhance quality of life [3] - The company operates on six continents and has a portfolio that includes Energy Services, Industrial Chemicals, and Critical Minerals [3] - TETRA provides products and services to the oil and gas industry and calcium chloride for various applications, while also expanding into the low-carbon energy market [3] Upcoming Event - TETRA's senior management will participate in the Virtual Lytham Partners Spring 2025 Investor Conference on May 29, 2025 [1] - Key executives including the CEO, CFO, and VP of Investor Relations will present and host one-on-one meetings with institutional investors [1] - A webcast of the event will be streamed at 1:15 pm ET on May 29, with a replay available the following day [2]

Core Insights - Thiogenesis Therapeutics has initiated a Phase 2 clinical trial for TTI-0102, targeting the treatment of MELAS, an inherited mitochondrial disease [1][3] - The trial aims to assess the safety, tolerability, efficacy, and pharmacokinetics of TTI-0102 over a 6-month period, involving 12 patients [2][3] - TTI-0102 is designed to increase intracellular antioxidants and amino acids, addressing deficiencies in MELAS patients [3][8] Company Overview - Thiogenesis Therapeutics is a clinical-stage biotechnology company based in San Diego, focusing on developing disulfides that enhance intracellular antioxidant production [1][10] - The company is publicly traded on the TSX Venture Exchange and OTCQX, with a focus on treating serious pediatric diseases with unmet medical needs [10] Clinical Trial Details - The Phase 2 trial is a multi-country, multi-center study conducted in the Netherlands and France, with a randomized, double-blind, placebo-controlled design [2] - A total of 12 patients will be enrolled, with 8 receiving TTI-0102 and 4 receiving a placebo, followed by an interim analysis after 3 months [2] Disease Background - MELAS is characterized by symptoms such as seizures, muscle weakness, and fatigue, often presenting before the age of 20, and is caused by mitochondrial DNA mutations [4] - The disease affects approximately 4.1 per 100,000 of the population, making it one of the most prevalent inherited mitochondrial disorders [4] Product Information - TTI-0102 is an asymmetric disulfide and prodrug that acts as a precursor to cysteamine, aimed at restoring mitochondrial function by increasing levels of glutathione and taurine [8] - The prodrug formulation addresses limitations of first-generation thiol-based drugs, including short half-life and adverse side effects [8][9]

Group 1 - TETRA Technologies, Inc. will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City [1] - Senior management, including the CEO, CFO, and VP of Investor Relations, will host one-on-one meetings with institutional investors during the conference [1] - Investors interested in scheduling meetings can contact the company directly [2] Group 2 - TETRA Technologies, Inc. is an energy services and solutions company focused on environmentally conscious services [2] - The company operates on six continents and has a portfolio that includes Energy Services, Industrial Chemicals, and Critical Minerals [2] - TETRA is expanding into the low-carbon energy market, leveraging its chemistry expertise and global infrastructure to meet sustainable energy demands [2]